SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (20)
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
2022
-
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
BMC Psychiatry, Vol. 22, Núm. 1
-
The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0
Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
-
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations
Drugs, Vol. 80, Núm. 2, pp. 131-146
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
2019
2018
-
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)
Breast Cancer Research and Treatment
-
Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification
Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852
-
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634
2017
-
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
PLoS ONE, Vol. 12, Núm. 10
-
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189
2015
-
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy
Clinical Cancer Research, Vol. 21, Núm. 17, pp. 3995-4003
2014
-
Chemobrain: ¿podemos hablar de un daño cerebral adquirido por quimioterapia?
Trauma (Spain), Vol. 25, Núm. 3, pp. 143-149
-
Náuseas y vómitos inducidos por quimioterapia antineoplásica. ¿Perceptión o realidad?
Revisiones en Cancer, Vol. 28, Núm. 4, pp. 135-145
2012
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
Breast Cancer Research and Treatment, Vol. 134, Núm. 2, pp. 583-593
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
2010
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600